ReviewJournal of cellular biochemistry2012
Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma.
Review in Journal of cellular biochemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- The role of antioxidants in multiple myeloma: diagnostic, prognostic, and therapeutic applications: a narrative review.Therapeutic advances in hematology · 2026Review
- Impact of proteostasis workload on sensitivity to proteasome inhibitors in multiple myeloma.Clinical and experimental medicine · 2025Review
- Increased Expression of ITGB 3 in CLL Patient leukemia Cells by Exposure to Cold Physical Plasma and Plasma-treated Medium.International journal of molecular and cellular medicine · 2024Article
- Oxidative Stress and Inflammation in B-Cell Lymphomas.Antioxidants (Basel, Switzerland) · 2023Review
- Article
- Modulation of Cellular Redox Parameters for Improving Therapeutic Responses in Multiple Myeloma.Antioxidants (Basel, Switzerland) · 2022Review
- Article
- Review
- Radioprotective Agents and Enhancers Factors. Preventive and Therapeutic Strategies for Oxidative Induced Radiotherapy Damages in Hematological Malignancies.Antioxidants (Basel, Switzerland) · 2020Review
- Article
- Characteristics of BAFF and APRIL factor expression in multiple myeloma and clinical significance.Oncology letters · 2017Article
- Human MutT homologue 1 mRNA overexpression correlates to poor response of multiple myeloma.International journal of hematology · 2017Article
- Arsenic Trioxide Induces Apoptosis via Specific Signaling Pathways in HT-29 Colon Cancer Cells.Journal of cancer science & therapy · 2017Article
- Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cells.Oncotarget · 2016Article
- Oxidative stress and proteasome inhibitors in multiple myeloma.Pharmacological research · 2016Review
- Drug metabolism and clearance system in tumor cells of patients with multiple myeloma.Oncotarget · 2015Article
- Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma.Redox biology · 2015Article
- A novel model of chronic wounds: importance of redox imbalance and biofilm-forming bacteria for establishment of chronicity.PloS one · 2014Article
- Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma.Leukemia research · 2013Article
- Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.Experimental hematology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Developing novel combined-modality therapeutic approaches based on understanding of the involvement of redox biology in apoptosis of malignant cells is a promising approach for improving clinical responses in B-cell lymphoma and multiple myeloma. Therapeutic modalities that generate reactive oxygen species (i.e., radiation, photodynamic therapy, and specific chemotherapeutic drugs) have been shown to be selectively cytotoxic to malignant B-cells. In this review, we will discuss agents that induce apoptosis in B-cell tumors by oxidative stress. Subsequently, a novel biochemical rationale (based on fundamental differences in cancer vs. normal cell oxidative metabolism) for combining oxidative stressors with radiotherapy and chemotherapy, that may lead to designing of more effective treatment strategies for B-cell malignancies, will be discussed. Besides providing potential curative benefit, such novel therapies could also selectively target and inhibit the emergence of drug-resistance in tumor cells, which is a major determinant of treatment failure in many B-cell malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.